Prescient Therapeutics Ltd has released a press release.
December 2019 Appendix 4C - Quarterly
Filed with ASX ·
6ix hasn’t read this filing yet.
Prescient Therapeutics Limited on 6ix
Story so far
Earlier from Prescient Therapeutics
- PTX-200 High Overall Response in Ph2a Breast Cancer trial
- Encouraging data from PTX-200 ovarian cancer trial
- Third complete response in PTX-200 AML Trial
- PTX in new CAR-T collaboration
- 1st patient dosed in trial for first in class drug PTX-100
Later from Prescient Therapeutics
- March 2020 Quarterly Update and Appendix 4C
- PTX-100 progresses to new dose, adds new site
- Pause in Trading
- Voluntary Suspension
- PTX signs next-gen anti-cancer platform from Penn & Oxford
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics